Fate Therapeutics: $306.7M cash runway through YE26; FT819 Phase 1 dose expansion in SLE underway

FATE THERAPEUTICS INC

Cash, cash equivalents and investments of $306.7M; projected operating runway through year-end 2026.
Initiated Phase 1 dose expansion of FT819 CAR T in SLE with flu-free conditioning (bendamustine or cyclophosphamide alone).
First SLE patient treated with FT819 as add-on to maintenance therapy without conditioning; no DLTs, CRS, or ICANS.
Completed Type D meeting with FDA to allow FT819 expansion into AAV, IIM, SSc; multi-dose and re-treatment permitted.
Q4 total operating expenses $63.6M, including $14.7M non-cash impairment; revenue $1.9M from Ono collaboration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.